Investors



Interim Summary

TurnoverQ3 2019

16 416

TSEK

EBITDAQ3 2019

-4 029

TSEK

Christer Ahlberg
President and CEO

CEO Comments

THE THIRD QUARTER has been intense, both in terms of clinical development and preparation for our European launch. During the quarter, we also made progress in Asia through a distribution agreement in India. In terms of sales, the third quarter was a good quarter with growth of 29 percent.

The most important progress in the quarter have mainly been made in the area of clinical development and I particularly want to highlight the work on the European study. The patient recruitment proceeds as planned and the work of compiling and consolidating the results has begun. Thanks to the three Slovenian clinics that were included in August / September, we expect to be able to complete the study according to plan in December 2019 or in January 2020. With that in mind, we will be able to communicate the overall results about 3 months after the last patient in. We will be able to submit our application for a market approval in the summer of 2020 in 16 European countries in a first registration round and probably we can have a European market approval in the second half of 2021.

When it comes to the preparations for our pediatric study, they have progressed well during the quarter. The most important milestone is that we got AnaConDa approved for use in children, which is a prerequisite for starting the study in 2020. The approval also means that AnaConDa can be used in patients with severely impaired lung function and all together, this means that we have no restrictions on the use of AnaConDa, and we can address the entire market for mechanically ventilated intensive care patients. The pediatric study ensures a complete application for registration and thus ten years of market exclusivity in the EU. We are also pleased that the European Medicines Agency EMA wants the study protocol to be designed to show that inhalation sedation via AnaConDa is better than midazolam, which is today’s standard treatment for children. That means our therapy can be evaluated to be a first-hand treatment.

We also had the first meetings with the investigators in the pediatric study. At these meetings, the study protocol is reviewed and discussed in great detail in order to optimize investigators involvement. In its way, our clinical activities coincide with our commercial ones. Starting the pediatric study in several countries could be regarded as a pre-launch. We have close to 20 clinics in Germany, Sweden, France and Spain where we expect that the knowledge and interest in using our therapy will be huge at the time of launch.

In terms of our commercial work, we are now increasing the pace and we are developing our medical, sales and marketing departments in order to prepare for the launch of IsoConDa with our own sales organization in the largest European markets. This is the main reason why our expenses increased during the quarter. For example, a first major English seminar was held in Birmingham. It was very well attended by prospective customers. About 70 physicians and other healthcare professionals set aside a full day to hear about the benefits of inhalation sedation. Through the seminar we started our work in the UK seriously and we continue to participate in major international congresses. During the quarter we participated, amongst others, at ESICM in Berlin, which is one of the world’s largest intensive care congresses.

After the end of the quarter, we made a successful private placement of SEK 375 million before costs. The money will primarily be used to finance the way to market approval for AnaConDa and IsoConDa in the USA. The combination registration of AnaConDa and IsoConDa includes activities such as two clinical studies involving a total of approximately 500 patients, human factors validation programs, toxicity studies, safety database, adaptation of the European pediatric study to FDA requirements and application for market approval (NDA).

We started the human factors validation program together with Harvard during the quarter and expect it to be completed in the summer of 2020. As far as the toxicity studies are concerned, we have started preparatory investigations and expect these to be ready in the summer of 2020. This enable us to plan to submit our IND application to the FDA in the fourth quarter of 2020 in order to begin clinical studies in 2021 in USA. We have already begun to find clinics that want to collaborate with us and work closely with advisory boards at each clinic. Our ambition is to have a good geographical spread at our American clinics in order to secure the commercially important regions. The plan is to reach US approval in 2024 and around 2022 we will decide whether to launch ourselves or together with local partners.

After the end of the quarter, we also announced that we are part-financing the study SESAR, the world’s largest multi-center study, with AnaConDa. The purpose is to show that inhalation sedation with AnaConDa has lung protective properties. The study covers 700 patients and has the potential to dramatically change the perception of inhalation sedation in relation to intravenous sedation. The study is being conducted in France and is sponsored to a large extent by the French Ministry of Health and the EU, which we consider to be a huge success for our therapy. If the study supports the hypothesis that inhalation sedation via AnaConDa has therapeutic effects, leads to shorter ventilator treatment and a higher survival rate, it will be an important breakthrough for ICU patients worldwide with severe lung disease.

In addition to our ambition to grow 20% per year before the registration of IsoConDa in Europe, we have previously also stated that we will deliver an EBITDA result that is not significantly negative. As registration gets closer, the work of building up larger medical, sales and marketing organizations in and outside of Europe has intensified and we no longer provide an EBITDA forecast for the time before registration. We clarify that our sales turnover target of SEK 500 million and the EBITDA margin target of about 40 percent three years after the European registration of IsoConDa only apply to Europe. Sales outside Europe, for example sales in China and Japan are not included in this target and we do not communicate forecasts for these markets at this time.

In summary, we have experienced another strong quarter that takes us closer to our goals; to register IsoConDa in Europe in the second half of 2021, to obtain market approval in the US in 2024 and to establish ourselves in the major markets in Asia. The goals are a first step towards our vision of making inhalation sedation with AnaConDa and IsoConDa a standard treatment for mechanically ventilated patients in intensive care worldwide. Our estimate of the total market potential for inhalation sedation in intensive care is SEK 20- 30 billion annually. Through the private placement, we got a number of new investors and I want to take this opportunity to thank you for the trust given to us by both old and new owners. I look forward to the continued journey with you all.

Christer Ahlberg, President and CEO

 Read the report in its entirety here.

Calendar
Dates for upcoming information

Date Event
20-21 Nov 2019 Jefferies 2019 London Healthcare Conference
27 Nov 2019 VATOR SECURITIES UNICORN SUMMIT 2019
3 Mar 2020 CARNEGIE NORDIC HEALTHCARE SEMINAR, 3-4 MARCH 2020
5 Mar 2020 Year-end report 2019
22 Apr 2020 Annual report 2019
3-4 Jun 2020 Nordic Mid/Small Cap Seminar 2020

Annual & Interim Reports

2016
Annual Reports Interim Reports
2016  Sedana Medical AB (publ)
Annual Report 2016 (in Swedish)
N/A N/A

Click on the + sign to expand reports on desired year, then click on a report to open it.
You need a pdf reader to view the files.

Content

Annual General Meeting 2019

Notice of Annual General Meeting in Sedana Medical AB 2019

Downloadable files:

Annual General Meeting 2018

Notice of Annual General Meeting in Sedana Medical AB (publ)
The shareholders in Sedana Medical AB (publ) are hereby summoned to attend the Annual General Meeting on Tuesday 22 May 2018 at 4 p.m. at. Erik Penser Bank, Apelbergsgatan 27, Stockholm. Registrations starts 15:30 CET.

Participation
Shareholders who wish to attend the Annual General Meeting must be listed as shareholders in the register kept by Euroclear Sweden AB on Wednesday, May 16, 2018, and must notify the company of their intention to participate in the meeting no later than Wednesday, May 16, 2018 at the following address: Sedana Medical AB (publ), Berga Backe 2, 182 53 Danderyd, Sweden. The registration can also be done by telephone +46 (0) 8- 124 05 200 or by e-mail to corp@sedanamedical.com. In the registration, name, address, telephone number (daytime), person / organization number, shareholding and information about possible representatives / assistants must be stated. There are a total of 17,280,538 shares and votes in Sedana Medical AB (publ). Shareholders represented by proxy shall issue a written, day-to-day power of attorney for the proxy or, should the right to vote for the shares be divided among different representatives, the representatives, together with information on the number of shares each representative is entitled to vote for. If the power of attorney is issued by a legal entity, a certified copy of the registration certificate or equivalent of the legal entity evidencing the authority to issue the proxy, shall be appended. The original power of attorney and any registration certificate should be sent to the company well before the meeting at the above address. Proxy form is available on the company’s website, www.sedanamedical.com. Shareholders who have registered in a nominee register by bank or securities depository must, in order to be entitled to participate in the meeting, register the shares in their own name. Such registration, which may be temporary, must be duly effected in the share register maintained by Euroclear Sweden AB on Wednesday, May 16, 2017, which means that the shareholders must notify the nominees well in advance of this date. Shareholders are reminded of their right to request information under Chapter 7. Section 32 of the Swedish Companies Act.

Proposed agenda
1. Opening of the meeting
2. Election of Chairman of the Meeting
3. Preparation and approval of the voting list
4. Election of two persons to approve the minutes of the meeting
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Presentation of the annual report and the auditor’s report, the consolidated accounts and the consolidated audit report
8. Statement by the CEO, Christer Ahlberg
9. Resolution on approval of the statement of income and balance sheet and consolidated income statement and
consolidated balance sheet.
10. Resolution on allocation of the company’s earnings according to the established balance sheet
11. Resolution on discharge from liability of the members of the Board of Directors and the Managing Director
12. Determination of fees to the Board of Directors and the Auditor
13. Determination of the number of Board members and, where applicable, deputy members, as well as the number of auditors and any deputy auditors
14. Election of Board of Directors and Auditor and any deputy members
15. Resolution on principles for appointment and instruction regarding nomination committee
16. Resolution regarding authorization for the Board of Directors to issue new shares
17. Closing of the Meeting

Proposition for resolutions
Resolution on allocation of the company’s result (item 10)
The board of directors proposes that the company’s results shall be carried forward.

Board etc. (item 2 and 12–14)
Nomination Committee, consisting of:

  • Karl Tobieson, Chairman of the Nomination Committee and representing Linc AB
  • Sten Gibeck, owner and board member of Sedana Medical AB (publ)
  • Ola Magnusson, owner and board member of Sedana Medical AB (publ)
  • Tony McCarthy, representing Michael Ryan
  • Proposes the following:
  • Thomas Eklund to be elected chairman of the meeting (item 2).
  • The Board of Directors shall consist of six (6) members and no deputies. The Company shall have one Auditor and no deputy auditors. (item 13).
  • A total fee to the Board of Directors of SEK 525,000, of which SEK 225,000 to the Chairman of the Board, SEK 50,000 each to Sten Gibeck, Bengt Julander, Ola Magnusson and Michael Ryan, and SEK 100,000 to Eva Walde. (item 12).
  • Fees to the auditor in accordance with the approved invoice. (item 12).
  • Re-election of the board members Thomas Eklund, Sten Gibeck, Bengt Julander, Ola Magnusson och Michael Ryan and election of Eva Walde as new member of the board (item 14). Further information regarding the proposed board members to be found at www.sedanamedical.com.
  • Re-election of Thomas Eklund as Chairman of the Board (item 14).
  • Re-election of R3 as an audit company with mandate until the 2019 Annual General Meeting (item 14).

Principles for the appointment of the Nomination Committee and instructions for the Nomination Committee (item 15)
It is proposed that the AGM decides to establish principles for the appointment of the Nomination Committee in accordance with the following.

Principles of determination
The chairman of the board shall, by the end of the third quarter of Sedana Medical’s financial year each year, ensure that the company’s voting three largest shareholders or ownership groups are invited to each appoint each member to be included in the nomination committee. The reconciliation is based on Euroclear Sweden AB’s shareholder list (owner group) as of the last banking day in September or any other evidence that shareholders or group of owners at this time report as evidence of their shareholding. Where one or more shareholders refrain from appointing a member of the Nomination Committee, one or more of the following shareholders in ownership shall be offered to appoint a member of the Nomination Committee. However, no more than five additional shareholders need not to be contacted, unless the Chairman of the Board finds that there are special reasons for this. When shareholders are contacted with a request for the appearance of a member of the Nomination Committee, the Chairman of the Board shall make the necessary rules of procedure such as the latest response date, etc.

The Nomination Committee shall consist of a total of at least three members, including the Chairman of the Board, which is included in the Nomination Committee and convenes the first meeting of the Nomination Committee.

The composition of the Nomination Committee shall be published as soon as it has been appointed. The chairman of the nomination committee shall, unless the members agree otherwise, be the member appointed by the largest shareholder. However, the Chairman of the Board or other Board member shall not be the Chairman of the Nomination Committee. The Nomination Committee shall hold its mandate until a new Nomination Committee has been appointed. Fees shall not be paid to members of the Nomination Committee. The member shall leave the nomination committee if the shareholder who appointed this member no longer has substantially the same ownership interest as when the member was appointed. If the Nomination Committee subsequently ceases to have at least three members, the Chairman of the Board shall act for a new member to be appointed according to the principles stated above. However, if there are no special reasons, no changes shall be made to the composition of the Nomination Committee if only minor changes in the voting number have taken place or the change occurs later than two months before the AGM.

Shareholders who appoint a member of the Nomination Committee are entitled to vacate such a member and appoint a new member of the Nomination Committee.

Nomination Committee assignment
The Nomination Committee shall prepare and propose to the Annual General Meeting:

  • election of chairman of the meeting
  • election of the chairman or members of the board of directors in the company’s board of directors
  • election of auditor and, if applicable, auditor’s deputy
  • proposals for remuneration to the chairman, board members, auditor and, where appropriate, committee work
  • principles for the election of the nomination committee

The Chairman of the Board shall appropriately inform the Nomination Committee of information about the Board’s competence profile and working methods.

Meetings
The Nomination Committee shall meet when required to fulfill its duties, at least twice a year. Notice of attendance is issued by the Chairman of the Nomination Committee (except for the first meeting convened by the Chairman of the Board). The member may request that the Nomination Committee be convened.

The nomination committee is to decide if at least half of the members participate. However, decisions in cases may not be taken, as far as possible, all members could participate in the matter. The decision of the Nomination Committee applies to the opinion for which more than half of the members present vote, or, in the same number of votes, the meaning of the nomination committee’s chairman.

An account of the Nomination Committee’s work in the form of proposals and opinions from the Nomination Committee shall be published on the Company’s website in good time before the Annual General Meeting.

Changes to these instructions
The Nomination Committee shall regularly evaluate these instructions and the nomination committee’s work and submit to the Annual General Meeting proposals for such changes to this instruction deemed appropriate by the Nomination Committee.

Authorization for the board to resolve on new issue of shares (item 16)
The Board of Directors proposes that the Annual General Meeting authorizes the Board to resolve on a number of occasions prior to the next Annual General Meeting, with or without prejudice to shareholders’ preferential rights, a new issue of shares which, in aggregate, does not exceed 15 percent of the total number of outstanding shares after use of the authorization. A new issue may be issued with or without notice regarding the amount, offsetting or other conditions referred to in Chapter 13, Section 5, first paragraph, 6 of the Swedish Companies Act. The purpose of the authorization is to give the board flexibility in the work to ensure that the company can be appropriately allocated capital for the financing of the business, business or product acquisition, and to enable the company’s ownership base to be broadened.

*****

The annual report and other supporting documentation for resolutions will be available at the company’s offices, Sedana Medical AB (publ), Berga Backe 2, 182 53 Danderyd, and on www.sedanamedical.com, no later than three weeks prior to the meeting and will be sent to shareholders who so request and provide their postal address. All of the above documents will also be presented at the meeting. This notice is a translation of a Swedish notice and in case of any deviations between the both language versions, the Swedish version shall prevail.

Stockholm, April 2018, Sedana Medical AB (publ)
The Board of Directors

Downloadable files:

  Notice of Annual General Meeting
  Nomination Committee’s proposal
  Power of Attorney form
  Minutes of the Annual General Meeting


Corporate Governance

Corporate governance includes information about our Board of Directors, the management team, guidelines for remuneration to the senior management, our auditors, general meetings and our articles of association.

Board of Directors

The registered office of the company is situated in the municipality of Danderyd. The Board of Directors shall consist of not less than three (3) and not more than six (6) members, with not more than three (3) deputy members. Currently the Board of Directors consists of six (6) members elected at the Annual General Meeting on 22 May 2018 for the period until the end of the next Annual General Meeting.

Thomas Eklund Chairman
of the Board
  • Born: 1967
  • Position: Board member and Chairman of Sedana Medical since 2014.
  • Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.
  • Other current engagements: Chairman in Biotage AB. Board member in Boule Diagnostics AB, Caliditas Theraputics AB, Excillum Aktiebolag, Immedica Pharma Holding AB, Memira Holding AB, Rodebjer Form AB, SciBase Holding AB (publ), Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 416,616 shares via Eklund Konsulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Sten GibeckMember
of the Board
  • Born: 1943
  • Position: Member of the Board of Sedana Medical since 2005. Formerly Chairman of the Board.
  • Education and professional experience: Sten holds a higher business economics qualification from the National Swedish Union of Clerical Employees. Sten is a former owner and CEO of Louis Gibeck AB during its journey from being a small distribution company to achieving a leading position in its field in e.g. Germany, France, Japan and the USA.
  • Other current engagements:
  • Shareholding in Sedana Medical: 1,605,744 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Bengt Julander Member
of the Board
  • Born: 1953
  • Position: Member of the Board of Sedana Medical since 2011.
  • Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Board member of Linc AB, with investments in the pharmaceutical and medtech industry.
  • Other current engagements: Chairman in Knil AB. Board member in Animal Probiotics
    Sweden AB, Calliditas Therapeutics AB, Cronhamn Invest AB, Linc AB, Livland Skog AB, Medivir Aktiebolag, Nefecon AB, nWise AB, Part Production Sweden AB, Reison Medical AB, Stille AB, Swevet AB and Swevet Holding AB. Deputy Board member in Eriksbergskliniken AB and board member and deputy board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 2,116,901 shares via Linc AB.
    Independent in relation to the Company and its management but not in relation to major shareholders.
Ola Magnusson
Member
of the Board
  • Born: 1948
  • Position: Member of the Board of Sedana Medical since 2005. Formerly CEO of Sedana Medical (2005 – 2011).
  • Education and professional experience: Ola holds an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry in Pharmacia and Kabi and 20 years of experience in the medical device industry in Louis Gibeck AB (CEO) and Hudson RCI as managing director EMEA.
  • Other current engagements: Chairman in Eataway AB and Transcutan AB. Board member in Hammarplast Medical Aktiebolag, Miris AB, Miris Holding AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,340,867 shares privately and via Magiola Consulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Eva Walde Member
of the Board
  • Born: 1963
  • Position: Member of the Board of Sedana Medical since 2018.
  • Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.
  • Other current engagements: Currently working as a self-employed management consultant, CEO and Chairman of the board in Movits Consulting AB and also deputy board member in Finnson & Partners AB.
  • Shareholding in Sedana Medical: 3, 200 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.

Management team

Christer Ahlberg
President and CEO
  • Born: 1971
  • Position: President and Chief Executive Officer of Sedana Medical since February 2017.
  • Education and professional experience: Christer holds a BSc in business administration and economics from Örebro University.Former experience in the pharmaceutical industry includes CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth.
  • Other current engagements: Board member in FrostPharma AB. CEO and deputy board member in Waxholm by the sea aktiebolag.
  • Shareholding in Sedana Medical: 230,000 shares and 184,200 warrants in program 2017/2021 representing 184,200 shares.
Maria Engström
CFO
  • Born: 1972
  • Position: Chief Financial Officer of Sedana Medical since February 2017.
  • Education and professional experience: Maria holds a BSc in business administration and economics from Stockholm University. Former managing director at Cross Pharma AB (2015–2016) and Head of Business Control at Medivir AB (2012–2014). More than 15 years of experience in positions as finance manager, head of business control and controller at Biovitrum, Bristol Myers Squibb and Ericsson.
  • Other current engagements: Board Member in FAYSIT – Finance At Your Service In Tyresö AB.
    Deputy board member in UHT Förvaltning AB.
  • Shareholding in Sedana Medical: 3,850 shares and 60,782 warrants in program 2017/2021 representing 60,782 shares via FAYSIT – Finance At Your Service In Tyresö AB.
Peter Sackey
CMO
  • Born: 1971
  • Position: Chief Medical Officer of Sedana Medical since January 2018.
  • Education and professional experience: Peter received his doctor´s degree from Karolinska Institutet in 1997. He has worked for twenty years at the Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital and is Board-certified in Anesthesiology (DESA) and Intensive Care (EDIC). He completed his PhD thesis entitled “Isoflurane sedation in Intensive Care Unit patients” at Karolinska Institutet in 2006. He is an Associate professor at Karolinska Institutet, has supervised several PhD students and has active ICU-related research.
  • Previous positions: Senior Consultant, Head of Neurocritical Care, Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital in Stockholm.
  • Other current engagements: Associate professor, Department of Physiology and Pharmacology, Karolinska Institutet.
  • Shareholding in Sedana Medical: 975 shares, 65,167 warrants in program 2017/2021 representing 65,167 shares and 26,293 warrants in program 2019/2022 representing 26,293 shares.
Ron Farrell
Vice President Head of R&D and Quality
  • Born: 1956
  • Position: Vice President Head of R&D and Quality at Sedana Medical since 2011. COO of Sedana Medical Ltd.
  • Education and professional experience: Ron has a graduateship in Plastics and Rubber from the Institute of London (GPRI). More than 37 years of experience in the manufacturing industry at e.g. Oral-B Laboratories, Gillette, Vistakon, Tech Group, Artema Medical and Kayfoam Woolfson. Main areas of competence include engineering, quality assurance, supply chain, development and operation management.
  • Other current engagements: Board member in Lismed Ltd. and Sedana Medical Ltd.
  • Shareholding in Sedana Medical: 831,062 shares.
Robert vom Dorp
Vice President Head of Sales
  • Born: 1970
  • Position: Vice President Head of Sales at Sedana Medical since 2010, employee since 2005.
  • Education and professional experience: Robert holds an MBA in economics from the University of Applied Sciences at Hochschule Koblenz. Has also studied industrial organisation. Experience in sales in the medtech industry since 2001 as account manager within anaesthesia, ventilation and intensive care at Hudson RCI and Teleflex Medical. Sales manager at Sedana Medical with responsibilities for marketing, sales, strategy and operations in Germany, Austria and Switzerland.
  • Other current engagements:
  • Shareholding in Sedana Medical: 111,500 shares.
Donat O’Brien
General Manager Manufacturing, Supply and Logistics
  • Born: 1958
  • Position: General Manager Manufacturing, Supply and Logistics at Sedana Medical, employed since December 2018.
  • Education and professional experience: Donat holds BA/MA degrees from University College Dublin and an MBA from Dublin City University. Donat has over 20 years’ experience of Supply Chain in paper, packaging and forest products with Union Camp/International Paper based in Ireland, Finland, Russia and Belgium. More recently Donat moved to pharmaceuticals, initially with Aspen Pharmaceuticals and then Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals) where, as Head of Supply Chain – International.
  • Other current engagements:
  • Shareholding in Sedana Medical:

Guidelines for remuneration to senior management

The main principle is that remuneration and other employment conditions for members of senior manage¬ment shall be based on market terms and be competitive in order to ensure that the group can attract and retain competent senior managers at a reasonable cost for the company.

The total remuneration for senior management shall consist of fixed salary, variable remuneration, pension and other benefits.

The Board fee is decided by the Annual General Meeting. In so far as board members elected by the Annual General Meeting are performing work that stretches beyond the tasks of the Board of Directors, it shall be possible to pay them for such work. Such remuneration shall be market-based and shall be approved by the Board of Directors.

At the Annual General Meeting on 19 May 2017 it was resolved that the fees payable to the Board of Directors for the period until the end of the Annual General Meeting 2018 shall amount to a total of SEK 350,000, of which SEK 150,000 shall be paid to the Chairman of the Board of Directors and SEK 50,000 to each of the other ordinary board members.

Auditor

Christina Kallin Sharpe, authorised public accountant at R3 Revisionsbyrå was re-elected as auditor for the company until the end of the next Annual General Meeting.

General Meeting

The General Meeting of shareholders is the highest decision-making entity in Sedana Medical AB. At the General Meeting, all shareholders are invited to exercise their rights according to their respective shareholdings.

Shareholders wishing to participate in General Meetings must be listed as a shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

Articles of Association

§ 1 Name of the company
The name of the company is Sedana Medical AB (publ).

§ 2 Registered office of the Board of Directors
The registered office of the company shall be situated in the municipality of Danderyd.

§ 3 Object of the company’s activities
The object of the company’s activities is to develop, manufacture and market pharmaceuticals and medical-technical products, and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 800,000 and not more than SEK 3,200,000.

§ 5 Number of shares
The number of shares shall be not less than 8,000,000 and not more than 32,000,000.

§ 6 Board of Directors
The Board of Directors shall consist of not less than three (3) and not more than six (6) members with not more than three (3) deputy members. The members are to be elected annually at the Annual General Meeting until the end of the next Annual General Meeting.

§ 7 Auditors
The company shall have a minimum of one (1) and a maximum of two (2) auditors, with a maximum of two (2) deputy auditors.

§ 8 Place of General Meetings
Any General Meeting of the company shall be held in Danderyd or Stockholm.

§ 9 Notice of General Meeting
Notices of General Meetings shall be made by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. At the same time as notice is given it shall be announced in Dagens industri that a notice has been made.
Shareholders wishing to participate in General Meetings must be listed as shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. The last mentioned date may not be a Sunday, other public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday before the general meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

§ 10 Annual General Meeting
The following matters shall be addressed at the Annual General Meeting:

1. Election of Chairman of the meeting

2. Preparation and approval of the voting register

3. Election of one or two persons to attest the minutes

4. Determination of whether the meeting has been duly convened

5. Approval of the agenda

6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated financial statements and the auditor’s report on the group

7. Resolutions regarding:

(a) adoption of the balance sheet and income statement and, where applicable, the consolidated balance sheet and the consolidated income statement

(b) disposition av bolagets vinst eller förlust enligt den fastställda balansräkningen

(c) discharge from liability for the Board of Directors and the managing director

8. Determination of fees to be paid to the Board of Directors and the auditors

9. Determination of the number of board members and, where applicable, deputy members, and the number of auditors and, where applicable, deputy auditors

10. Election of the Board of Directors and auditors

11. Any other business incumbent on the meeting according to the Swedish Companies Act or the articles of association

§ 11 Financial year
The company’s financial year shall be 1 January – 31 December.

§ 12 CSD clause
The shares of the company shall be registered in a CSD register in accordance with the Central Securities Depositaries and Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

Ownership

Below is Sedana Medical’s ownership structure as of October 31, 2019.

Name Number of shares Shareholding (%)
Linc AB 2 116 901 9,31%
Handelsbanken funds 1 655 713 7,28%
Anders Walldov direct and indirect (Brohuvudet AB) 1 600 000 7,04%
Sten Gibeck 1 530 744 6,73%
Swedbank Robur funds 1 376 600 6,05%
Ola Magnusson direct and indirect (Magiola AB) 1 340 867 5,90%
Anades Ltd. 1 143 083 5,03%
Ron Farrell 631 062 2,78%
Berenberg funds 712 731 3,13%
Nordnet Pension Insurance 490 904 2,16%
Avanza Pension 488 284 2,15%
Öhman Funds 452 671 1,99%
Eklund Konsulting AB 416 616 1,83%
Tredje AP fonden 357 069 1,57%
Tony McCarthy 339 823 1,49%
Fifteen largest shareholders 14 653 068 64,45%
Others * 8 083 523 35,55%
TOTAL: 22 736 591 100%

* Of which CEO’s ownership is 230 000 shares.

Source: Modular Finance

Warrant programmes

Sedana Medical has three outstanding warrant programmes with a total maximum dilution of 1 720 149 shares.

Warrant program 2014/2019, total maximum dilution of 1 040 000 shares, exercisable until 31 December 2019
at a strike price of 2,50 SEK/share.

Warrant program 2017/2021, total maximum dilution of 310 149 shares, exercisable until 31 January 2021
at a strike price equaling 130% of the IPO price.

Warrant program 2019/2022, total maximum dilution of 370 000 shares, exercisable until 30 November 2022
at a strike price of 142,23 SEK per share.

Presentations

Date Description Material
September, 2019 Sedana Medical – Management Presentation September 2019.  View Presentation
June 10, 2019 Redeye Growth Day 2019.  Play Video
May 8, 2019 Presentation of the interim report for the first quarter 2019.  Play Video
March 14, 2019 Stockholm Corporate Finance Life Science Seminar.  Play Video
March 8, 2019 IsoConDa phase III pivotal study, interim analysis report, 8 March 10:30.  Play Video
September 6, 2018 Pareto Securities’ 9th Health Care seminar in Stockholm.  Play Video
April 27, 2018 Event at ProHearings (English).  Play Video
March 7, 2018 Sitdown at Erik Penser 2018 (Swedish).  Play Video
March 6, 2018 Stockholm Corporate Finance Life Science Seminar (Swedish).  Play Video
November 24, 2017 Redeye seminar (Swedish).  Play Video
June 29, 2017 Trading Direkt Interview with CEO Christer Ahlberg (Swedish).  Play Video

Shares

Share
ISIN-code
Share
Shortname
Current
Share Price
SE0009947534 SEDANA  Click here!
Certified Adviser: Erik Penser Bank – Tel: +46 (0)8-463 80 00 – Apelbergsgatan 27, Box 7405, 103 91 Stockholm, Sweden
Analyst(s) covering Sedana Medical: Christian Lee, Pareto Securities

IPO

 Sedana Medical Investor Relation

 

Address:
Sedana Medical AB (publ)
Vendevägen 87
SE-182 32 Danderyd
Sweden
Phone: +46 (0)8-124 05 200
Investor relation: ir@sedanamedical.com


Sign up for news

Sign up and be up-to-date with the latest news about us, delivered right to your inbox!
Click here to sign up for news